Childhood Cancer Treatment, Genetics Contribute to Subsequent Neoplasm Risk
FRIDAY, June 13, 2025 -- Cancer treatments and genetic predisposition contribute to the risk of subsequent neoplasms (SNs) among long-term childhood cancer survivors, according to a study published online in the June issue of The Lancet Oncology.
Achal Neupane, Ph.D., from St. Jude Children's Research Hospital in Memphis, Tennessee, and colleagues analyzed data from the St. Jude Lifetime Cohort (SJLIFE; 4,401 participants) and the Childhood Cancer Survivor Study (CCSS; 7,943 participants) to estimate the relative contributions of radiotherapy and chemotherapy exposures, genetic predisposition, and lifestyle factors on the risk of SNs in survivors of childhood cancer.
The median follow-up was 24.2 and 28.0 years in SJLIFE and CCSS, respectively. The researchers found that cancer treatments and genetic risk jointly contributed to a substantial proportion of incident SN cases with attributable fractions varying from 30 to 92 percent for sarcoma and meningioma, respectively. Higher exposure levels of radiotherapy contributed most, especially in older versus younger (≥35 years versus <35 years) follow-up age periods (SJLIFE participants: proportion of SNs, 44.7 versus 40.0 percent, respectively). A notable proportion was accounted for by elevated genetic risk based on polygenic risk scores, ranging from 1 to 52 percent for meningioma and thyroid cancers, respectively, surpassing the contributions of chemotherapies. Negligible contributions were seen for lifestyle factors.
"Now that we have quantified the contributions of treatment, genetics, and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect, and treat these cancers, and hopefully extend these survivors' lives," coauthor Yadav Sapkota, Ph.D., also from St. Jude Children's Research Hospital, said in a statement.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Features of Immunesenescence Present in Early Stages of Rheumatoid Arthritis
THURSDAY, Sept. 11, 2025 -- Some features of immunesenescence are present in the very early stages of rheumatoid arthritis (RA), according to a study published online Sept. 3 in...
Urine Biomarker Panel Sensitive, Specific for Prostate Cancer Diagnosis
THURSDAY, Sept. 11, 2025 -- A urine-based biomarker panel has high accuracy for diagnosing prostate cancer (PCa), according to a study published in the September issue of...
Deescalated Radiotherapy Tolerated After Surgery for HPV-Linked Oropharyngeal Cancer
THURSDAY, Sept. 11, 2025 -- For patients following surgery for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma, a deescalated regimen of adjuvant...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.